Related Experiment Video
Updated: Jun 8, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines
1Department of Endocrinological and Medical Sciences and Center of Excellence for Biomedical Research, Università degli Studi di Genova, 16132 Genova, Italy.
Abstract:
Somatostatin analogues inhibit in vitro cell proliferation via specific membrane receptors (SSTRs). Recent studies on transfected cell lines have shown a ligand-induced formation of receptor dimers. The aim of this study is 1) to evaluate the role of specific ligands in modulating receptor interactions in the androgen-dependent prostate cancer cell line, LNCaP, and in the non-small cell lung cancer line, Calu-6, by co-immunoprecipitation and immunoblot; and 2) to correlate the antiproliferative effect of these compounds with their ability in modulating receptor interactions. In LNCaP, we have demonstrated the constitutive presence of sstr₁/sstr₂, sstr₂/sstr₅, sstr₅/dopamine (DA) type 2 receptor (D₂R), and sstr₂/D₂R dimers. BIM-23704 (sstr₁- and sstr₂-preferential compound) increased the co-immunoprecipitation of sstr₁/sstr₂ and significantly inhibited proliferation (-30.98%). BIM-23244 (sstr₂-sstr₅ selective agonist) significantly increased the co-immunoprecipitation of sstr₂/sstr₅, and induced a -41.36% inhibition of proliferation. BIM-23A760, a new somatostatin/DA chimeric agonist with a high affinity for sstr₂ and D₂R and a moderate affinity for sstr₅, significantly increased the sstr₅/D₂R and sstr₂/D₂R complexes and was the most powerful in inhibiting proliferation (-42.30%). The chimeric compound was also the most efficient in modulating receptor interaction in Calu-6, increasing the co-immunoprecipitation of D₂R/sstr₅ and inhibiting cell proliferation (-30.54%). However, behind BIM-23A760, BIM-53097 (D₂R-preferential compound) also significantly inhibited Calu-6 proliferation (-17.71%), suggesting a key role for D₂R in receptor cross talk and in controlling cell growth. Indeed, activation of monomeric receptors did not affect receptor co-immunoprecipitation, whereas cell proliferation was significantly inhibited when the receptors were synergistically activated. In conclusion, our data show a dynamic ligand-induced somatostatin and DA receptor interaction, which may be crucial for the antiproliferative effects of the new analogues.
Insights
New somatostatin and dopamine receptor interactions, triggered by specific ligands, significantly inhibit cancer cell proliferation. This highlights a crucial link between receptor cross-talk and the antiproliferative effects of novel drug analogues.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Somatostatin analogues (SSTRs) inhibit cell proliferation through membrane receptors.
- Ligand-induced receptor dimerization is a known mechanism.
- Understanding receptor interactions is key to developing targeted cancer therapies.
Purpose of the Study:
- To investigate ligand-induced somatostatin and dopamine receptor interactions in prostate (LNCaP) and lung (Calu-6) cancer cells.
- To correlate these receptor interactions with the antiproliferative effects of novel analogues.
Main Methods:
- Co-immunoprecipitation and immunoblot assays to detect receptor dimers.
- Cell proliferation assays to measure antiproliferative effects.
- Use of specific somatostatin and dopamine receptor agonists.
Main Results:
- Specific ligands modulated somatostatin and dopamine receptor dimerization in LNCaP and Calu-6 cells.
- Increased receptor dimerization correlated with significant inhibition of cell proliferation.
- A novel somatostatin/dopamine chimeric agonist demonstrated potent antiproliferative effects by modulating receptor interactions.
Conclusions:
- Ligand-induced somatostatin and dopamine receptor interactions play a critical role in cancer cell proliferation.
- Synergistic activation of dimeric receptors, rather than monomeric ones, is crucial for antiproliferative effects.
- These findings support the development of novel analogues targeting receptor cross-talk for cancer therapy.
